Abstract
Mer kinase is a novel cancer therapeutic target. Abnormal activation or overexpression of Mer kinase has been implicated in several human cancers. Three-dimensional quantitative structure–activity relationship (3D-QSAR) and molecular docking studies were performed on a series of pyridinepyrimidine derivatives to understand the structural basis for Mer kinase inhibitory activity. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) methods were used to derive 3D-QSAR models. The CoMFA model produced statistically significant results with a cross-validated correlation coefficient (q 2) of 0.634 and a non-cross-validated correlation coefficient (r 2) of 0.968. The reliable CoMSIA model with q 2 of 0.665 and r 2 of 0.991 was obtained from the combination of steric, electrostatic, hydrophobic, hydrogen bond acceptor and hydrogen bond donor fields. The CoMFA and CoMSIA models showed reasonable predictive abilities with predicted correlation coefficient (r 2pred ) of 0.629 and 0.811, respectively. The models were further evaluated by leave-five-out cross-validation and bootstrapping analyses. Docking studies were carried out to deduce probable binding conformations of this series of inhibitors inside the active site of Mer kinase. Docking studies also contributed to the identification of some crucial binding residues in the active site. The correlation of 3D-QSAR and docking results indicated the robustness of the QSAR models. Overall, a combined application of docking and 3D-QSAR results could provide a better understanding of the interactions between the inhibitors and protein. This study could assist in the design of novel compounds with enhanced Mer kinase inhibitory activity.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Balupuri A et al (2013) In silico study on indole derivatives as anti HIV-1 agents: a combined docking, molecular dynamics and 3D-QSAR study. Arch Pharm Res 37:1001–1015
Balupuri A et al (2014) Docking-based 3D-QSAR study of pyridyl aminothiazole derivatives as checkpoint kinase 1 inhibitors. SAR QSAR Environ Res 25:651–671
Brandão L et al (2011) TAM receptors in leukemia: expression, signaling, and therapeutic implications. Crit Rev Oncog 16:47–63
Chen J et al (1997) Identification of Gas6 as a ligand for Mer, a neural cell adhesion molecule related receptor tyrosine kinase implicated in cellular transformation. Oncogene 14:2033–2039
Chen C et al (2004) Mer receptor tyrosine kinase signaling participates in platelet function. Arterioscler Thromb Vasc Biol 24:1118–1123
Clark M et al (1989) Validation of the general purpose Tripos 5.2 force field. J Comput Chem 10:982–1012
Cramer RD et al (1988a) Crossvalidation, bootstrapping, and partial least squares compared with multiple regression in conventional QSAR studies. Quant Struct Act Relatsh 7:18–25
Cramer RD et al (1988b) Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J Am Chem Soc 110:5959–5967
Gadhe CG et al (2012) Large variation in electrostatic contours upon addition of steric parameters and the effect of charge calculation schemes in CoMFA on mutagenicity of MX analogues. Mol Simul 38:861–871
Gasteiger J, Marsili M (1980) Iterative partial equalization of orbital electronegativity—a rapid access to atomic charges. Tetrahedron 36:3219–3228
Gjerdrum C et al (2010) Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival. Proc Natl Acad Sci USA 107:1124–1129
Graham DK et al (2006) Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia. Clin Cancer Res 12:2662–2669
Keating A et al (2006) Lymphoblastic leukemia/lymphoma in mice overexpressing the Mer (MerTK) receptor tyrosine kinase. Oncogene 25:6092–6100
Klebe G et al (1994) Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J Med Chem 37:4130–4146
Koorstra J et al (2009) The Axl receptor tyrosine kinase confers an adverse prognostic influence in pancreatic cancer and represents a new therapeutic target. Cancer Biol Ther 8:618–626
Lemke G, Rothlin CV (2008) Immunobiology of the TAM receptors. Nat Rev Immunol 8:327–336
Li Y et al (2009) Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis. Oncogene 28:3442–3455
Linger R et al (2008) TAM receptor tyrosine kinases: biologic functions, signaling, and potential therapeutic targeting in human cancer. Adv Cancer Res 100:35–83
Linger RM et al (2010) Taking aim at Mer and Axl receptor tyrosine kinases as novel therapeutic targets in solid tumors. Expert Opin Ther Targets 14:1073–1090
Linger RM et al (2010) Mer and Axl receptor tyrosine kinases are novel therapeutic targets in NSCLC. In: AACR-IASLC Joint Conference on Molecular Origins of Lung Cancer-Prospects for Personalized Prevention and Therapy. Coronado, CA
Linger RM et al (2013) Mer receptor tyrosine kinase is a therapeutic target in pre–B-cell acute lymphoblastic leukemia. Blood 122:1599–1609
Liu J et al (2013) UNC1062, a new and potent Mer inhibitor. Eur J Med Chem 65:83–93
Lu X et al (2014) Dose-effect relationship of celecoxib, a selective cyclooxygenase-2 inhibitor prevents lymphangiogenesis in a lewis lung carcinoma. Cancer Cell Res 1:9–18
Morris GM et al (1998) Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19:1639–1662
Morris GM et al (2009) AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem 30:2785–2791
Powell MJD (1977) Restart procedures for the conjugate gradient method. Math Program 12:241–254
Rochlitz C et al (1999) Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13:1352–1358
Sanner MF (1999) Python: a programming language for software integration and development. J Mol Graph Model 17:57–61
Sather S et al (2007) A soluble form of the Mer receptor tyrosine kinase inhibits macrophage clearance of apoptotic cells and platelet aggregation. Blood 109:1026–1033
Tai K et al (2008) Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1. Oncogene 27:4044–4055
Wold S et al (1984) The collinearity problem in linear regression. The partial least squares (PLS) approach to generalized inverses. SIAM J Sci Comput 5:735–743
Yeoh EJ et al (2002) Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell 1:133–143
Zhang W et al (2013a) Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis. J Med Chem 56:9693–9700
Zhang W et al (2013b) Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors. J Med Chem 56:9683–9692
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Balupuri, A., Balasubramanian, P.K. & Cho, S.J. Molecular modeling study on Mer kinase inhibitors using 3D-QSAR and docking approaches. Med Chem Res 24, 3730–3742 (2015). https://doi.org/10.1007/s00044-015-1416-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-015-1416-7